


**This publication is for sale at our website** [http://csdd.tufts.edu/reports]

Getz, KA. Finally, standardized KPIs are front and center. *Applied Clinical Trials*. 2016; 25(10/11):24-25 [RS 3629]
http://www.appliedclinicaltrialsonline.com/finally-standardized-kpis-are-front-and-center


http://www.appliedclinicaltrialsonline.com/assessing-global-clinical-supply-logistics


http://dx.doi.org/10.1007/s40264-016-0455-4

http://dx.doi.org/10.1002/cpt.502

http://dx.doi.org/10.1038/nrd.2016.104

http://www.appliedclinicaltrialsonline.com/insights-capturing-collaborative-value

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
Lamberti MJ, Chakravarthy R, Getz K. *Assessing practices & inefficiencies with site selection, study start-up, and site activation. Applied Clinical Trials. Online publish date: Aug 5, 2016 [RS 3620]

*Note: Article subsequently appears in print publication with a different title: New benchmarks for trial initiation activities. Applied Clinical Trials. (Dec 2016/Jan 2017);25(12): 28-32.


http://www.samedanltd.com/magazine/11/issue/255/article/4390


http://dx.doi.org/10.1177/2168479016648730


http://dx.doi.org/10.1002/jcph.762


http://dx.doi.org/10.1177/2168479016650716


Getz KA. Acknowledging cycle time impact from protocol amendments. Applied Clinical Trials. 2016;25(4/5) [RS 3612b]


**This publication is for sale at our website http://csdd.tufts.edu/reports
http://dx.doi.org/10.1007/s40264-016-0425-x

http://dx.doi.org/10.1016/j.clinthera.2016.02.031


Kaitin KI, editor. Optimizing collaboration Effectiveness in Alliance Partnerships Boston: Tufts Center for the Study of Drug Development; 2016 R&D Senior Leadership Brief. (Lamberti, Chakravarthy, Getz) [RS 3609b]


http://dx.doi.org/10.1177/2168479016632271

http://dx.doi.org/10.1016/j.jhealeco.2016.01.012

http://www.appliedclinicaltrialsonline.com/clinical-trial-knowledge-missed-gained-and-shared


**This publication is for sale at our website  http://csdd.tufts.edu/reports
http://dx.doi.org/10.1208/s12248-015-9833-6


http://dx.doi.org/10.1177/2168479015625712


Kaitin KI, editor. Amendments reduce number of patients, but at high cost, longer study times. Tufts Center for the Study of Drug Development Impact Report. 2016 Jan/Feb;18(1)** [RS 3601]


Getz KA. New look at the arsenal of technology solutions. Applied Clinical Trials 2015;24(10/11):16-17. [RS 3540b]


http://dx.doi.org/10.1038/nrd4759

**This publication is for sale at our website http://csdd.tufts.edu/reports


http://www.pharmoutsourcing.com/Featured-Articles/177660-The-Unintended-Inefficiencies-of-Outsourcing-Practice/


http://dx.doi.org/10.1002/cpt.194

http://dx.doi.org/10.1016/j.clinthera.2015.07.004

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1016/j.clinthera.2015.05.514

http://www.pharmafocusasia.com/strategy/personalised-medicines

http://dx.doi.org/10.1007/s40264-015-0310-z


http://dx.doi.org/10.1136/bmj.h3333

Getz KA. Characterizing the real cost of site regulatory compliance. *Applied Clinical Trials*. 2015;24(6/7):18,20. [RS 3526b]
http://www.appliedclinicaltrialsonline.com/characterizing-real-cost-site-regulatory-compliance


http://dx.doi.org/10.1177/2168479015587362

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1007/s40291-015-0138-3


http://dx.doi.org/10.1016/j.clinthera.2015.02.026


http://www.appliedclinicaltrialsonline.com/closing-opportunities-simplify-protocol-design

http://www.pharmexec.com/meeting-unmet-medical-needs-disparity-dilemma-0


http://dx.doi.org/10.1377/hlthaff.2014.1047

http://dx.doi.org/10.1377/hlthaff.2014.1023


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.2217/bmm.14.84

http://dx.doi.org/10.2217/bmm.14.66


Stergiopoulos S, Surgeon L. The facilitated clinical trial protocol review: is the theory being put into good practice? *Chimica Oggi [Chemistry Today]*. 2014;32(6):52-56. [RS 3439]  

Cohen JP. Is Ebola diverting resources from other neglected diseases? *The Conversation*. Online publish date: December 8, 2014. [RS 3438b]  
http://theconversation.com/is-ebola-diverting-resources-from-other-neglected-diseases-34475

Kaitin KI, editor. CNS drugs take longer to develop, have lower success rates, than other drugs. *Tufts Center for the Study of Drug Development Impact Report*. 2014 Nov/Dec;16(6)** [RS 3438]

http://dx.doi.org/10.1016/j.clinthera.2014.09.008

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
Getz, KA. Is 'Open Integration' beyond our reach? *Applied Clinical Trials.* 2014;23(10/11):16,18 [RS 3436b]  
http://www.appliedclinicaltrialsonline.com/open-integration-beyond-our-reach


**Cost Study Press Event Webcast and Briefing, November 18, 2014**  
To access materials related to the Cost Study click here:  
http://csdd.tufts.edu/news/complete_story/cost_study_press_event_webcast


Kaitin KI. Integrated partnerships and the transformation of pharmaceutical research and development. *Clinical Therapeutics.* 2014;36(10):1346-1348 [RS 3434]  
http://dx.doi.org/10.1016/j.clinthera.2014.09.007

Cohen JP. Patient access to orphan drugs faces new set of challenges. *Formulary.* Online publish date: September 15, 2014. [RS 3433]  


http://dx.doi.org/10.5639/gabij.2014.0303.028


**This publication is for sale at our website  http://csdd.tufts.edu/reports**

http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=845307&pageID=1&sk=&date=

http://dx.doi.org/10.1016/j.clinthera.2014.05.004


Getz KA. Q&A with Jean Burns: Insights from a study volunteer. *Applied Clinical Trials Online*. Online publish date: May 28, 2014. [RS 3422]


http://dx.doi.org/10.3390/ijerph110505069

http://dx.doi.org/10.1002/9781118783344.ch1

**This publication is for sale at our website** http://csdd.tufts.edu/reports

Getz KA. Coming to terms with interrupted drug development programs. *Applied Clinical Trials.* 2014;23(4/5):22-23. [RS 3417b]

http://dx.doi.org/10.1038/nrd4325

http://dx.doi.org/10.1038/clpt.2014.14


http://www.manhattan-institute.org/html/fda_07.htm#.U1_t61dUinw


http://csdd.tufts.edu/reports/ebooks

http://dx.doi.org/10.3390/jpm4020163

http://dx.doi.org/10.1177/2168479014525957


Milne C-P, Davis J. The Pediatric studies initiative: after 15 years have we reached the limits of the law? *Clinical Therapeutics*. 2014;36(2):156-162. [RS 3407]
http://dx.doi.org/10.1016/j.clinthera.2013.11.007


http://dx.doi.org/10.4155/cli.13.134

http://dx.doi.org/10.1177/2168479014521419


**This publication is for sale at our website http://csdd.tufts.edu/reports**
http://dx.doi.org/10.3402/jmahp.v2.23513


http://dx.doi.org/10.1371/journal.pone.0084088

http://dx.doi.org/10.1038/clpt.2013.177

http://cognoscenti.wbur.org/2013/12/18/series-prescription-drug-pipeline-sidney-wolfe-kenneth-kaitin


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=828039


http://dx.doi.org/10.1586/17512433.2013.841539

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
Getz KA. Leveraging pharmacists as a channel to raise clinical research literacy among patient communities. *Applied Clinical Trials*. 2013;22(10):30-33. [RS 3337]
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Ang-Pharmacists-as-a-Channel-to-Raise-Clini/ArticleStandard/Article/detail/825673


http://www.scripintelligence.com/home/Flexible-global-more-adaptive-clinical-trials-2.0-346528


http://dx.doi.org/10.1038/clpt.2013.129


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Ang-Pharmacists-as-a-Channel-to-Raise-Clini/ArticleStandard/Article/detail/820680


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1517/21678707.2013.819289

http://dx.doi.org/10.1038/clpt.2013.117


http://dx.doi.org/10.1177/2168479013494386

Milne CP. On the partnering path from the US to Asia: how far, how fast for university-industry collaborations? *Pharma Focus Asia*. 2013;(18):40-45. [RS 3323]
http://www.pharmafocusasia.com/strategy/partnering-path-us-asia


http://dx.doi.org/10.1016/j.clinthera.2013.04.004

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website http://csdd.tufts.edu/reports**

http://dx.doi.org/10.1377/hlthaff.2012.0707

http://dx.doi.org/10.1016/j.clinthera.2012.12.018

http://dx.doi.org/10.1016/j.cct.2013.02.007

http://dx.doi.org/10.1177/2168479013478953


Getz KA, Stergiopoulos S, Marlborough M, Whitehill J, Curran M, Kaitin KI. Quantifying the magnitude and cost of collecting extraneous protocol data. *American Journal of Therapeutics*. 2013. [Published Ahead-of-Print; Last Updated: April 9, 2013] [RS 3307]
http://dx.doi.org/10.1097/MJT.0b013e31826fc4aa


http://dx.doi.org/10.1097/MJT.0b013e318269198f


Kaitin KI, editor. 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. *Tufts Center for the Study of Drug Development Impact Report.* 2013 Jan/Feb;15(1)** [RS 3302]

http://dx.doi.org/10.1177/2168479012469947


http://dx.doi.org/10.1016/j.anai.2012.11.014

http://dx.doi.org/10.1634/theoncologist.2012-0235


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

[http://dx.doi.org/10.1586/ecp.12.44](http://dx.doi.org/10.1586/ecp.12.44)

[http://dx.doi.org/10.1007/s12031-012-9803-8](http://dx.doi.org/10.1007/s12031-012-9803-8)


[http://dx.doi.org/10.1097/MJT.0b013e318262316f](http://dx.doi.org/10.1097/MJT.0b013e318262316f)


[http://dx.doi.org/10.1007/BF03262374](http://dx.doi.org/10.1007/BF03262374)


Kaitin KI. Translational research and the evolving landscape for biomedical innovation. *Journal of Investigative Medicine.* 2012;60(7):995-998 [RS 3228]  
[http://dx.doi.org/10.231/JIM.0b013e318268694f](http://dx.doi.org/10.231/JIM.0b013e318268694f)

[http://dx.doi.org/10.1586/erp.12.25](http://dx.doi.org/10.1586/erp.12.25)

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://dx.doi.org/10.1177/0092861512453040


http://dx.doi.org/10.1038/clpt.2012.87


http://www.pharmafocusasia.com/research_development/application-Biopharmaceutics-Classification-System-Drug-Development.htm


Getz KA. Outsourcing landscape. *Applied Clinical Trials.* 2012;21(5)(suppl):S22-S26 [RS 3217]
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Feature+Article/Outsourcing-Landscape/ArticleStandard/Article/detail/772232

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://dx.doi.org/10.1016/j.drudis.2012.04.006

http://dx.doi.org/10.4161/mabs.19931


http://dx.doi.org/10.1586/ecp.12.7

http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=763940&sk=&date=&&pageID=1

http://dx.doi.org/10.1136/medethics-2011-100411

http://dx.doi.org/10.1016/j.nbt.2012.02.001

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.4161/mabs.4.2.18812


Getz KA. Profound changes in the outsourcing landscape. *Pharmaceutical Executive.* Published February 29, 2012. [web document] [RS 3206]

http://dx.doi.org/10.1038/nrd3677

http://dx.doi.org/10.1038/clpt.2011.338


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Kaitin KI. Creating innovation nodes to meet unmet medical needs. *Pharmaceutical Technology.* 2011;35(12):27 [RS 3132]

Getz KA. Transforming legacy R&D through open innovation. *ACRP Monitor.* 2011;25(7):17-21 [RS 3131b]

http://dx.doi.org/10.1089/pop.2011.0020


http://dx.doi.org/10.1038/tpj.2011.63

Wilson A, Cohen J. Patient access to new cancer drugs in the United States and Australia. *Value in Health.* 2011;14:944-952 [RS 3127]
http://dx.doi.org/10.1016/j.jval.2011.05.004

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.4161/mabs.3.5.17334

http://www.biopharminternational.com/biopharm/FinalWord/The-Case-for-Pediatric-Exclusivity/ArticleStandard/Article/detail/750858

http://pharmtech.findpharma.com/pharmtech/Drug+Delivery/The-Case-for-Pediatric-Exclusivity/ArticleStandard/Article/detail/738366

http://dx.doi.org/10.1586/ecp.11.45

http://dx.doi.org/10.2217/pme.11.51


http://dx.doi.org/10.1038/scientificamerican0811-16

http://dx.doi.org/10.4161/mabs.3.4.16589


http://dx.doi.org/10.1177/009286151104500403

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1177/009286151104500406

http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=730576

Kaitin KI. 21st Century innovation: academic-industry partnerships are increasingly important in biopharmaceutical innovation. *Pharmaceutical Technology.* 2011;35(6):32 [RS 3119]
http://pharmtech.findpharma.com/pharmtech/article/articleDetail.jsp?id=724982&sk=&date=&&pageID=1

http://www.emaud.org/Doc/Market_Access_Newsletter_EMAUD_June%202011.pdf


Reichert JM. The amazing, multipurpose antibody. *mAbs.* 2011;3(3):221-222. [RS 3116b]
http://dx.doi.org/10.4161/mabs.3.3.15625

http://dx.doi.org/10.2217/pme.11.38

http://dx.doi.org/10.1177/009286151104500316

http://dx.doi.org/10.1177/009286151104500307

http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=719542&sk=9270beba3a37ef7e37f3fa5477eaa1ef9%22

**This publication is for sale at our website** http://csdd.tufts.edu/reports

Kaitin KI, editor. New or modified indications for existing drugs have steadily increased in the U.S. *Tufts Center for the Study of Drug Development Impact Report*. 2011 Mar/Apr;13(2)** [RS 3111]

http://dx.doi.org/10.4161/mabs.3.2.14788

http://dx.doi.org/10.1177/009286151104500203

Getz KA. Low hanging fruit in the fight against inefficiency. *Applied Clinical Trials*. 2011;20(3):30-32 [RS 3109]  
http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Articles/Low-Hanging-Fruit-in-the-Fight-Against-Inefficiency/ArticleStandard/Article/detail/711311?contextCategoryId=37194

http://dx.doi.org/10.1038/clpt.2010.286


Getz KA. The ultimate act of appreciation of study volunteers. *Focus*. 2011;3:8-12 [RS 3106b]  

http://dx.doi.org/10.4161/mabs.3.1.13895

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


http://dx.doi.org/10.1038/nrd3296

http://dx.doi.org/10.1177/009286151104500106

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=703033&sk=&date=&pageID=2


Reichert JM. Metrics for antibody therapeutics development. *mAbs.* 2010;2(6):695-700 [RS 3029]
http://dx.doi.org/10.4161/mabs.2.6.13603

http://dx.doi.org/10.1038/clpt.2010.167

http://dx.doi.org/10.1038/nbt1110-1160

Getz KA. Hurry up and wait, pharma puts the brakes on strategic outsourcing partnering. *Inside Outsourcing.* 2010 Nov;10-16 [RS 3026b]
http://www.nxtbook.com/nxtbooks/advanstar/insideoutsourcing_201011/#/12

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=693552


Getz KA. Providing results to volunteers. *Applied Clinical Trials*. 2010;19(10):52-59 [RS 3023b]  

http://license.icopyright.net/rights/tag.act?tag=3.7442%3ficx_id=686210

http://dx.doi.org/10.1038/nrd3229

http://dx.doi.org/10.1002/hec.1538


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=673673&sk=&date=&pageID=3


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

RS 3016d  Getz KA. Engaging pharmacists in research education. *Applied Clinical Trials*. 2010;19(7):30-32  
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=678141

http://dx.doi.org/10.1038/clpt.2010.86

http://dx.doi.org/10.4161/mabs.12369

http://dx.doi.org/10.1093/jnci/djq246


http://dx.doi.org/10.1371/journal.pone.0010610


RS 3012  Getz K. FIPNet: Pharma’s new, sexy, but not yet ready for print-time model. *Applied Clinical Trials*. 2009;Suppl:10-12,14,16

Author manuscript; available in PMC 2011 August 4. PMCID: PMC3150117  

**This publication is for sale at our website  http://csdd.tufts.edu/reports
RS 3010b  Getz KA. Conversations with study volunteers. *Applied Clinical Trials*. 2010;19(5):32-34  
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/Conversations-With-Study-Volunteers/ArticleStandard/Article/detail/668513


RS 3009  Getz KA. Sizing up the clinical research market. *Applied Clinical Trials*. 2010;19(3):32-34  
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=660749

RS 3008  Getz KA. With clinical data, less is more. *Applied Clinical Trials*. 2010;19(1):28-30  
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/With-Clinical-Data-Less-is-More/ArticleStandard/Article/detail/652123

http://dx.doi.org/10.1093/protein/gzq018

RS 3007b  Getz KA. Understanding clinical trials: Appreciating medical heroes. *Media Planet*. 2010 Apr  


http://dx.doi.org/10.4161/mabs.2.2.11320

http://dx.doi.org/10.1097/MJT.0b013e3181ca7f10


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
[http://dx.doi.org/10.1038/clpt.2009.293](http://dx.doi.org/10.1038/clpt.2009.293)

[http://dx.doi.org/10.1038/clpt.2009.295](http://dx.doi.org/10.1038/clpt.2009.295)

[http://dx.doi.org/10.4161/mabs.2.1.10628](http://dx.doi.org/10.4161/mabs.2.1.10628)

RS 3002b  Reichert JM. Antibodies to watch in 2010. *MAbs*. 2010;2(1):84-100;  
[http://dx.doi.org/10.4161/mabs.2.1.10786](http://dx.doi.org/10.4161/mabs.2.1.10786)


RS 2934  Getz KA  Vogel JR. Successful outsourcing: tracking global CRO usage. *Applied Clinical Trials Online*. 2009 Aug 17  

[http://dx.doi.org/10.2217/pme.09.40](http://dx.doi.org/10.2217/pme.09.40)


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://dx.doi.org/10.1017/S0266462309090072


http://dx.doi.org/10.1126/scitranslmed.3000222


http://dx.doi.org/10.1007/BF03256155


http://dx.doi.org/10.4161/mabs.1.6.10059


**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)

RS2921b  Getz KA.  Into the aftermath of M&A.  Applied Clinical Trials. 2009;18(9)  

RS 2921  Kaitin KI, editor.  Marketing exclusivity for first-in-class drugs has shortened to 2.5 years.  Tufts Center for the Study of Drug Development Impact Report. 2009 Sep/Oct;11(5)**

http://dx.doi.org/10.4161/mabs.1.5.9675

http://dx.doi.org/10.4161/mabs.1.4.9031


http://dx.doi.org/10.1177/009286150904300415

RS 2915  Cohen J.  Market access in the wake of NICE: biopharma’s friend or foe?  European Pharmaceutical Review. 2009;48:8-12  

http://www.fdli.org/resources/resources-order-box-detail-view/off-label-use-reimbursement

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=609455


http://dx.doi.org/10.4161/mabs.1.4.9076


http://dx.doi.org/10.4161/mabs.1.1.7645


http://dx.doi.org/10.4161/mabs.1.3.8590


http://www.pharmexec.com/pharmexec/Sales+Articles/Make-a-Match/ArticleStandard/Article/detail/592061

http://dx.doi.org/10.1038/nbt0409-331

**This publication is for sale at our website http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1177/009286150904300212

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=586863

http://dx.doi.org/10.1136/jme.2008.024711


http://dx.doi.org/10.4161/mabs.1.2.7946

http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=579328

http://dx.doi.org/10.1358/dnp.2009.22.1.1303819

http://dx.doi.org/10.4161/mabs.1.1.7246

http://dx.doi.org/10.2174/1874143600802010089


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=574844

http://dx.doi.org/10.2174/138920108786786358

http://dx.doi.org/10.4161/mabs.1.1.7646


RS 2833b  Getz KA. Should physicians enroll their own patients into clinical trials? *ACRP Monitor*. 2008 Dec;22(7):34-38

RS 2833  Kaitin KI. Offshoring cost effective clinical research. *Pharma Focus Asia*. 2008; (9):55-6  
http://www.pharmafocusasia.com/clinical_trials/offshoring_cost_effective_clinical_research.htm

http://dx.doi.org/10.1504/IJBT.2008.021307

RS 2831  Milne C-P  Bruss JB. The economics of pediatric formulation development for off-patent drugs. *Clinical Therapeutics*. 2008;30(11):2133-45  
http://dx.doi.org/10.1016/j.clinthera.2008.11.019

http://dx.doi.org/10.1038/nrd2733

http://dx.doi.org/10.1002/9780471462422.eoct382

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


http://dx.doi.org/10.1097/MJT.0b013e31816b9027


http://www.washingtonpost.com/wp-dyn/content/article/2008/09/26/AR2008092603126_pf.html


RS 2825b Getz KA. Getting to the heart of public distrust. *Applied Clinical Trials*. 2008;17(9):38-42


**This publication is for sale at our website http://csdd.tufts.edu/reports**

http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Clinical+Trial+Insights/Is-Investigative-Site-Feasibility-Feasible/ArticleStandard/Article/detail/527735

http://www.contractpharma.com/articles/2008/06/clinical-research-outsourcing

http://www.manhattan-institute.org/html/mpr_06.htm


http://dx.doi.org/10.1002/9780471462422.eoct336


http://dx.doi.org/10.1215/03616878-2007-054

http://dx.doi.org/10.1215/03616878-2007-063


Getz KA. Beyond outsourcing (interview by Jenefer Trevena). *Scrip Supplement Contract Research Update*. 2008;Apr;4:5-6

**This publication is for sale at our website  http://csdd.tufts.edu/reports**

http://dx.doi.org/10.1586/14737167.8.2.133


RS 2811  Getz KA.  The heavy burden of protocol design.  *Applied Clinical Trials.*  2008;17(5):38-40  

RS 2810  Getz KA.  Tackling racial disparities in research.  *Applied Clinical Trials.*  2008;17(1):40-42  

RS 2809  Getz KA.  In search of efficiency between trial phases.  *Applied Clinical Trials.*  2008;17(3):35-38  
http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Clinical+Trial+Insights/In-Search-of-Efficiency-Between-Trial-Phases/ArticleStandard/Article/detail/500433?contextCategoryId=37194

http://dx.doi.org/10.1097/MJT.0b013e31815fa75a


http://dx.doi.org/10.1177/009286150804200108

http://dx.doi.org/10.1016/j.drudis.2007.09.003

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
| RS 2804 | Cohen JP, Kaitin KI. Follow-on drugs and indications: the importance of incremental innovation to medical practice. *American Journal of Therapeutics*. 2008 Jan/Feb;15(1):89-91 [http://dx.doi.org/10.1097/MJT.0b013e31815f9e52](http://dx.doi.org/10.1097/MJT.0b013e31815f9e52) |
| RS 2802 | Kaitin KI. Obstacles and opportunities in new drug development. *Clinical Pharmacology & Therapeutics*. 2008;83(2):210-2 [http://dx.doi.org/10.1038/sj.clpt.6100462](http://dx.doi.org/10.1038/sj.clpt.6100462) |
| RS 2728 | DiMasi JA, Grabowski HG. Should the patent system for new medicines be abolished? *Clinical Pharmacology & Therapeutics*. 2007;82(5):488-90 [http://dx.doi.org/10.1038/sj.clpt.6100393](http://dx.doi.org/10.1038/sj.clpt.6100393) |

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 2721 Kaitin KI, editor. Despite more cancer drugs in R&D, overall U.S. approval rate is 8%. Tufts Center for the Study of Drug Development Impact Report. 2007 Sep/Oct;9(5)**


RS 2714 Getz KA. CRO shifts in the outsourcing market. Applied Clinical Trials. 2007;16(5):35-38

**This publication is for sale at our website http://csdd.tufts.edu/reports
RS 2713
http://dx.doi.org/10.1038/nrd2241

RS 2712

RS 2711
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=416536

RS 2710
Getz KA, Sergeant E, Kremidas J. Mission possible: rebranding clinical research. *Applied Clinical Trials*. 2007;16(4):35-6,8
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=416537

RS 2709
http://www.jstor.org/pss/30033224

RS 2708
Getz K, Wenger J. High times for the CRO heavyweights. *Scrip supplements*. 2007 Mar;5-6

RS 2707

RS 2706

RS 2705
http://dx.doi.org/10.2165/00124363-200620050-00003

RS 2704
Getz KA. Drowning in the sea of regulatory compliance. *Applied Clinical Trials*. 2007;16(2):32-34
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=401621

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.2165/00063030-200721010-00001

http://dx.doi.org/10.1200/JCO.2006.09.0803


RS 2625 Kaitin KI Milne C-P. Just another day at the office? The Scientist. 2006;20(12):49-50
http://www.the-scientist.com/?articles.view/articleNo/24559/title/Just-Another-Day-at-the-Office-/  

RS 2624b Cohen J Cairns C Paquette C Faden L. Comparing patient access to pharmaceuticals in the UK and US. Applied Health Economics and Health Policy. 2006;5(3):177-87
http://dx.doi.org/10.2165/00148365-200605030-00004

http://dx.doi.org/10.2165/00148365-200605040-00009

http://dx.doi.org/10.1111/j.1365-2710.2006.00777.x

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=382875

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Kaitin KI, editor. CRO contribution to drug development is substantial and growing globally. *Tufts Center for the Study of Drug Development Impact Report*. 2006 Jan/Feb;8(1)**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 2601  Getz KA. The imperative to support site adoption of EDC. *Applied Clinical Trials.* 2006;15(1):38-40  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=283027


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=261633

RS 2517  Getz KA. Have we pushed our PIs too far? *Applied Clinical Trials.* 2005;14(9):34-36  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=176904&&pageID=1

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172272

RS 2515  Milne C-P Kaitin KI. Down the critical path: who should lead? *Applied Clinical Trials.* 2005;14(8):56  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172279

http://dx.doi.org/10.2307/3564071

RS 2513  Sugarman J Getz K Speckman JL Byrne MM Gerson J Emanuel EJ  
http://dx.doi.org/10.1056/NEJM200504283521723

RS 2512  DiMasi JA Hansen RW Grabowski HG. Reply: setting the record straight on setting the record straight: response to the Light and Warburton rejoinder. *Journal of Health Economics.* 2005 Sep;24(5):1049-53  

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Kaitin KI, editor. Longer clinical times are extending time to market for new drugs in U.S. *Tufts Center for the Study of Drug Development Impact Report.* 2005 Nov/Dec;7(6)**

Reichert JM  Rosensweig CJ  Faden LB  Dewitz MC. Monoclonal antibody successes in the clinic. *Nature Biotechnology.* 2005;23(9):1073-8 http://dx.doi.org/10.1038/nbt0905-1073


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://dx.doi.org/10.1017/S0266462304001291

Milne C-P. Harbingers, or harvesters of change? *European Pharmaceutical Review Supplement (Outsourcing). 2004 Winter:12-17*

Reichert JM. Technology evaluation: Lumiliximab, Biogen Idec. *Current Opinion in Molecular Therapeutics. 2004;6(6):675-83*

Cohen JP  Paquette C  Cairns CP. Switching prescription drugs to over the counter. *BMJ. 2005 Jan 1;330(7481):39-41*
http://dx.doi.org/10.1136/bmj.330.7481.39


Cohen J. The emergence of a *de facto* fourth hurdle in the US. *Regulatory Affairs Journal – Pharma. 2004;15(12):867-70*
http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12516


http://dx.doi.org/10.1038/nbt1204-1513

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://dx.doi.org/10.1177/009286150403800301


http://dx.doi.org/10.1056/NEJM200405203502127

http://dx.doi.org/10.1177/009286150303700401


http://dx.doi.org/10.1038/nrd1386


**This publication is for sale at our website** http://csdd.tufts.edu/reports
http://dx.doi.org/10.1177/009286150403800105


http://dx.doi.org/10.1016/S1359-6446(04)03025-9


http://dx.doi.org/10.1177/009286150303700403

http://dx.doi.org/10.1076/jmep.28.3.327.14586

http://dx.doi.org/10.1177/009286150303700310

http://dx.doi.org/10.1345/aph.1D110

http://dx.doi.org/10.1097/00045391-200309000-00010


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 2312  Kaitin KI, editor. Switching drugs from prescription to OTC status on rise in U.S. and EU. *Tufts Center for the Study of Drug Development Impact Report.* 2003 Sep/Oct;5(5)**


http://dx.doi.org/10.1007/BF03257362

http://dx.doi.org/10.1038/nrd1178


http://dx.doi.org/10.2190/XD07-L5KF-YBFE-YB52


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1016/S0167-6296(02)00126-1

RS 2301  Kaitin KI, editor. Increased pressure on drug industry is leading to greater focus on Japan. *Tufts Center for the Study of Drug Development Impact Report.* 2003 Jan/Feb;5(1)**


http://dx.doi.org/10.2165/00019053-200220003-00011


RS 2218  Kaitin KI, editor. Approval times for new drugs fell by more than a year during PDUFA. *Tufts Center for the Study of Drug Development Impact Report.* 2002 Nov/Dec;4(6)**

http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=36729


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

RS 2203  Reichert JM  Therapeutic monoclonal antibodies: trends in development and approval in the US. Current Opinion in Molecular Therapeutics. 2002;4(2):110-8


RS 2123  Kaitin KI. El papel de la investigación básica. [editorial]. (Original title: The quest for cures -- the role of the research-based drug industry) La Vanguardia (Barcelona). 2001 18 Mar*


RS 2118b  Cohen J. The interaction of state, multistate, and federal initiatives to control prescription drug costs in the United States. Decision Resources. 2001 Sep;12:1-12


**This publication is for sale at our website  [http://csdd.tufts.edu/reports]**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1177/009286150103500108

http://dx.doi.org/10.1177/009286150103500109


Kaitin Ki, editor. FDA’s fast track program results in 62% approval rate after first 3 years. *Tufts Center for the Study of Drug Development Impact Report.* 2001 Jan/Feb;3(1)**

http://dx.doi.org/10.1016/S0939-6411(00)00131-4


http://dx.doi.org/10.1177/009286150003400425

Cross-functional team focus on marketing is key to project success. *Tufts Center for the Study of Drug Development Impact Report.* 2000 Dec;2(9)


**This publication is for sale at our website http://csdd.tufts.edu/reports**

RS 2008  Drug firms embrace pediatric study program during first 2 years of FDAMA. *Tufts Center for the Study of Drug Development Impact Report*. 2000 Apr;2(3)

http://dx.doi.org/10.1001/jama.283.15.2013


http://dx.doi.org/10.1177/009286150003400129


http://dx.doi.org/10.1177/009286150003400101


http://dx.doi.org/10.1177/009286159903300401


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.3109/10601339709019438


http://dx.doi.org/10.1097/00045391-199705000-00002


http://dx.doi.org/10.1097/00045391-199701000-00010

http://dx.doi.org/10.1038/nbt0297-130

RS 9715  Kaitin KI. FDA reform: setting the stage for efforts to reform the agency. *Drug Information Journal.* 1997;31(1):27-33
http://dx.doi.org/10.1177/009286159703100105

RS 9714  Lasagna L DiMasi JA. Let’s speed up the approval of new indications for old drugs. *Medical Marketing & Media* 1996;31(12):88-9

**This publication is for sale at our website**  http://csdd.tufts.edu/reports
http://dx.doi.org/10.1016/S0009-9236(96)90209-X

http://dx.doi.org/10.1177/009286159603000416

RS 9625  DiMasi JA.  *Written testimony.*  House Subcommittee on Human Resources and Intergovernmental Affairs, Committee on Government Reform and Oversight, U.S. House of Representatives. September 12, 1996


RS 9623  Kaitin KI.  *Statement.*  Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives. The Need for FDA Reform, February 27, 1996.  104th Congress 2d Session:81-7, 100-1


http://archive.wilsonquarterly.com/essays/research-dilemma


RS 9618  Welling PG  Lasagna L  Banakar UV, editors.  *The drug development process.*  New York; Marcel Dekker:1996*

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1177/00928615960300103


http://dx.doi.org/10.1097/00045391-199609000-00008


http://dx.doi.org/10.1177/009286159603000201


**This publication is for sale at our website**  http://csdd.tufts.edu/reports
http://dx.doi.org/10.2165/00019053-199609020-00004

http://dx.doi.org/10.1097/00004714-199512000-00001

http://dx.doi.org/10.1097/00045391-199509000-00023

http://dx.doi.org/10.1016/0009-9236(95)90240-6

http://dx.doi.org/10.1177/009286159502900227

RS 9506  Shulman SR  Seibring M  Manocchia M.  *Letter to Hon. Judd Gregg, U.S. Senate*. Hearing before the Subcommittee on Aging of the Committee on Labor and Human Resources, United States Senate, July 13, 1995. 104th Congress 1st Session:47-8


http://dx.doi.org/10.1097/00004714-199504000-00002


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1016/0009-9236(95)90066-7

http://dx.doi.org/10.1016/0009-9236(95)90078-0


http://dx.doi.org/10.1080/758519309

http://dx.doi.org/10.1177/009286159502900202

PS 9596  Brown JS DiMasi JA Gosse ME Manocchia M Kaitin KI Shulman SR. Incentives for the development of drugs for AIDS and other life-threatening illnesses: points to consider. For the Public/Private Issues and Development Subcommittees of the National Task Force on AIDS Drug Development meeting, April 25, 1995

http://dx.doi.org/10.2165/00019053-199507020-00007

RS 9594  Bloom BR. The United States needs a national vaccine authority. Science. 1994 Sep 2;265(5177):1378-80  
http://dx.doi.org/10.1126/science.8073275


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://www.fdli.org/mobile/resources-detail-view/?friendlyname=the-drug-export-amendments-act-of-1986-is-it-all-it-was-intended-to-be

http://dx.doi.org/10.1215/03616878-19-4-922


http://dx.doi.org/10.1002/j.1552-4604.1994.tb02044.x

RS 9496  Lasagna L.  *Statement of Louis Lasagna, M.D., Dean, Tufts Sackler School of Graduate Biomedical Sciences at the National Institutes of Health CRADA forum, July 21, 1994.*  Washington DC: New England Biomedical Research Coalition, 1994


**This publication is for sale at our website**  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)


Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News.* 1993 Nov;(8)


**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)

http://dx.doi.org/10.2165/00019053-199202050-00001

http://dx.doi.org/10.12.15/03616878-17-4-847

http://dx.doi.org/10.1002/j.1552-4604.1993.tb04680.x

http://dx.doi.org/10.1038/nbt0293-168


RS 9274  Shulman SR Raiford DS. Promotional elements in educational programs: FDA attempts to wipe the slate clean. P&T. 1992;17:661-73*


http://dx.doi.org/10.7326/0003-4819-115-4-315

**This publication is for sale at our website  http://csdd.tufts.edu/reports


RS 9266  Scoville B.  Shifting the burden: restructuring the drug review process.  Journal of Clinical Pharmacology and Therapeutics. 1991;49(3):229-33  http://dx.doi.org/10.1038/clpt.1991.21


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


Fernandez-Carol CM Kaitin KI. The generic scandal and FDA reforms. Pharmaceutical Medicine. 1991;5:13-17

Inman WHW. Drug Safety Research Unit, University of Southampton. PEM News. 1991 Aug;(7)


DiMasi JA Lasagna L. Development of supplemental indications for already-approved drugs by the United States pharmaceutical industry. Journal of Clinical Research and Pharmacoepidemiology. 1991;5:19-33


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 9054  Shulman SR.  La legislazione sulla responsabilità di produzione.  *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:27-8

RS 9053  Lasagna L.  Le attività del Centro per lo Studio dello Sviluppo dei Farmaci.  *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:26

RS 9052  Inman WHW.  Drug Safety Research Unit, University of Southhampton,  *PEM News*.  1988 Sep(5)


http://dx.doi.org/10.1177/009286159002400135

http://dx.doi.org/10.1177/009286159002400132

RS 9048  Shulman SR  Raiford DS.  FDA regulations provide broader access to unapproved drugs.  *Journal of Clinical Pharmacology*.  1990;30(2):585-7  
http://dx.doi.org/10.1002/j.1552-4604.1990.tb01860.x


http://dx.doi.org/10.1177/0092861589023000406


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


[http://dx.doi.org/10.2105/AJPH.79.11.1565](http://dx.doi.org/10.2105/AJPH.79.11.1565)

[http://dx.doi.org/10.1177/009286158802200104](http://dx.doi.org/10.1177/009286158802200104)


Kaitin KI. Reply to “understanding comparisons of drug introductions between the United States and the United Kingdom”. *Clinical Pharmacology & Therapeutics.* 1989 Aug;46(2):146-8
[http://dx.doi.org/10.1038/clpt.1989.118](http://dx.doi.org/10.1038/clpt.1989.118)


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1038/clpt.1989.116


RS 8934  Grabowski HG.  Medicaid patients' access to new drugs.  *Health Affairs* 1989;7:102-14  
http://dx.doi.org/10.1377/hlthaff.7.5.102

http://dx.doi.org/10.1001/jama.1988.03410150098038

http://dx.doi.org/10.1016/0273-2300(88)90007-4

http://dx.doi.org/10.1016/0273-2300(88)90013-X

RS 8930  Inman WHW.  Drug Safety Research Unit, University of Southampton.  *PEM News.* 1988 Sep;(5)


RS 8830  Shulman SR.  Drug refusal policy must include legal definition of competence.  *Hospital Formulary.* 1988 Jan;23:79

RS 8829  DiMasi JA.  The notion of "acceptable risk": comment.  *Journal of Clinical Epidemiology.* 1988;41(9):939-41  
http://dx.doi.org/10.1016/0895-4356(88)90111-4

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://dx.doi.org/10.1002/j.1552-4604.1988.tb05747.x

Wittes RE. Antineoplastic agents and FDA regulations: square pegs for round holes? *Cancer Treatment Reports.* 1987;71(9):795-806


http://dx.doi.org/10.1038/clpt.1988.35

http://dx.doi.org/10.1287/mnsc.33.3.381

http://dx.doi.org/10.1002/mde.4090070404


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1002/j.1552-4604.1987.tb03064.x


http://dx.doi.org/10.3109/10601338709032965


http://dx.doi.org/10.2131/jts.12.439


http://dx.doi.org/10.1038/clpt.1987.42

http://dx.doi.org/10.7326/0003-4819-106-6-886


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
RS 8710  Inman WHW.  Drug Safety Research Unit, University of Southampton, *PEM News*. 1987 Mar;(4)

http://dx.doi.org/10.1177/009286158501900327

http://dx.doi.org/10.1038/clpt.1986.192


http://dx.doi.org/10.1002/j.1552-4604.1986.tb02950.x

RS 8705  Kaitin KI.  Impact of generic drugs on the pharmaceutical marketplace. *Private Practice*. 1986 Sep;18:18-20  (Originally appeared as "Generic firms shun research, share rewards.")

http://dx.doi.org/10.1016/0273-2300(86)90006-1


http://dx.doi.org/10.1111/j.1365-2125.1987.tb03099.x

http://dx.doi.org/10.1001/jama.1986.03380180128035

***This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)***


http://dx.doi.org/10.1017/S0266462300003445


http://dx.doi.org/10.1080/00031305.1985.10479435

http://dx.doi.org/10.1111/j.1539-6924.1986.tb00194.x

RS 8600  Berry CL.  Unprovable verities.  *Human Toxicology.* 1985;5(3):159-60

RS 8699  Weintraub M  Northington F.  Drugs that wouldn't die.  *Journal of the American Medical Association.* 1986 May 2;255(17):2327-8
http://dx.doi.org/10.1001/jama.1986.03370170091042

http://dx.doi.org/10.1177/009286158602000105


RS 8696  Inman WHW.  Drug Surveillance Research Unit, University of Southampton.  *PEM News.* 1985 Dec;(3)

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Kitch E. Vaccines and product liability: a case of contagious litigation. Regulation. 1985 May/Jun


Walker SR Schultz E Schuppan D Gelzer J. A comparative retrospective analysis of data for short- and long-term animal toxicity studies on 40 pharmaceutical compounds. Archives of Toxicology. 1984; Suppl 7:485-7 http://dx.doi.org/10.1007/978-3-642-69132-4_102


Mattison N. Sources of change affecting the U.S. pharmaceutical industry in the 1980s. Pharmaceutical Medicine. 1985;1:89-96* http://dx.doi.org/10.1056/NEJM198503143121128


http://dx.doi.org/10.1002/j.1552-4604.1985.tb02819.x

http://dx.doi.org/10.1038/clpt.1985.54

http://dx.doi.org/10.1002/ddr.430040402


http://dx.doi.org/10.1038/clpt.1984.224


RS 8478  Lasagna L.  *Impediments to Vaccine Research, Medicine in the Public Interest Conference, Jan 9-10, 1984*. Boston: MIPI;1984

**This publication is for sale at our website**  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)
Inman WHW. Drug Surveillance Research Unit, University of Southampton, PEM News. 1984 Aug;(2)

http://dx.doi.org/10.1016/0273-2300(84)90038-2

http://dx.doi.org/10.1038/clpt.1984.78


Weintraub M. P&T committees and drug regulation in Norway: lessons to be learned. Hospital Formulary. 1984;19:347


http://dx.doi.org/10.2307/3564062


http://dx.doi.org/10.1056/NEJM198311243092105

Vane JR. Wellcome relief: new drugs for the Third World. The Health Sciences. 1982 Oct 15

Hutt PB. The importance of patent term restoration to pharmaceutical innovation: will extending patent life increase drug innovation? A search for answers. Health Affairs. 1982;1(2):5-24
http://dx.doi.org/10.1377/hlthaff.1.2.6


**This publication is for sale at our website http://csdd.tufts.edu/reports**


RS 8367  Superior Court of New Jersey, Appellate Division.  Carol Ann Feldman, an infant, by her parent and guardian *ad litem* Harold Feldman, Plaintiffs - Appellants vs. Lederle Laboratories, a corporation, and American Cyanamid Co., a corporation, Defendants - Respondents. Nov 1983

RS 8366  Inman WHW.  Drug Surveillance Research Unit, University of Southampton.  *PEM News*. 1983 Aug;(1)

RS 8365  Covington TR.  Toward a rational approach to the issue of prescribing authority for pharmacists.  *Drug Intelligence and Clinical Pharmacy*. 1983;17(9):660-6

[http://dx.doi.org/10.1038/clpt.1983.95](http://dx.doi.org/10.1038/clpt.1983.95)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1038/clpt.1983.73

http://dx.doi.org/10.1038/clpt.1982.181

http://dx.doi.org/10.1136/bmj.283.6289.477

http://dx.doi.org/10.1111/j.1365-2125.1981.tb01251.x


http://dx.doi.org/10.1007/BF00396431

http://dx.doi.org/10.1007/BF00332351

http://dx.doi.org/10.1016/S0272-0590(82)80089-4


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


RS 8262  Wardell WM. Is pharmaceutical innovation declining? *Pharmaceutical Technology.* 1982 Sep


RS 8260  Wardell WM Mattison N. The assessment of medical technologies using risk-benefit, cost-benefit, and cost-effectiveness analysis. In: *WMA Follow-up Committee on Development and Allocation of Medical Care Resources.* Tokyo: Japan Medical Association;1982;84-98*


http://dx.doi.org/10.1002/j.1552-4604.1982.tb02664.x


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 8253b Schweiker RS. Remarks by the Honorable Richard S. Schweiker to the National Pharmaceutical Council Symposium. June 23, 1982


http://dx.doi.org/10.1038/clpt.1982.34

RS 8250 Wardell WM. A statement on pharmaceutical patent life and innovation. Submitted to the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives. Feb 4, 1982


http://dx.doi.org/10.1001/jama.1981.03310450044021


RS 8153 Wardell WM Velo GP, editors. Drug development, regulatory assessment, and postmarketing surveillance. NATO Advanced Institutes Series, 39 (Series A: Life Sciences) New York: Plenum; 1981*
http://dx.doi.org/10.1007/978-1-4684-4055-3


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1016/0010-7824(81)90025-1  
http://dx.doi.org/10.1056/NEJM197912273012602  

---

[^368]: This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)
http://dx.doi.org/10.1056/NEJM197907053010110


Hansen RW. Effects of incremental costs on pharmaceutical innovation. (Working Paper Series No. GPB-81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

Hansen RW. The cost of regulation in the pharmaceutical industry: economic implications of three recent studies. (Working Paper Series No. PS 81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

Wardell WM. Therapeutic drugs as an example of the regulation of health care: efficient and inefficient ways of utilizing resources. In: *Proceeding of the World Medical Association Follow-Up Committee Meeting on Development and Allocation of Medical Care Resources*. Tokyo: Japan Medical Association, 1980:139-50*

Wardell WM. Drug therapy (a response to questions on specific aspects of drug regulation). *Private Practice*. 1980 Oct:24-31*


http://dx.doi.org/10.1002/j.1552-4604.1980.tb01660.x

Lasagna L. Pharmacology's labs have moved faster than the regulators. *Medical Tribune*. 1980 May 7;21:17

**This publication is for sale at our website**  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)
| RS 8046 | Hansen RW. *Pharmaceutical development costs by therapeutic categories.* (Working Paper Series No. GPB-80-6) Rochester, NY: Graduate School of Management, University of Rochester; Mar 1980* |

**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Letters to the editor. in re: the drug lag. Regulation. 1980 Mar/Apr;4(2):59-60


Merrill RA. Problems involving federal conflict of interest restrictions on members of FDA advisory committees and agency officials. Rochester, NY: Center for the Study of Drug Development; Apr 1980


**This publication is for sale at our website http://csdd.tufts.edu/reports**


RS 7939 Lasagna L. Toxicological barriers to providing better drugs. *Archives of Toxicology*. 1979;43(1):27-33 http://dx.doi.org/10.1007/BF00695871

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 7938  Lasagna L. Prescription drugs: the investment with the biggest dividends. Private Practice. 1979;11(5):42-3

http://dx.doi.org/10.1002/j.1552-4604.1979.tb02464.x

http://dx.doi.org/10.1002/j.1552-4604.1979.tb01649.x


RS 7930  Lasagna L. The uncertain future of drug development. Drug Intelligence and Clinical Pharmacy. 1979;13(4):192-4


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
RS 7927  Wardell WM. Rx: more regulation or better therapies. Regulation. 1979 Sep/Oct;3(5):25-33


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1007/BF01968666


RS 7823  Wardell WM. A close inspection of the 'calm look': rhetorical amblyopia and selective amnesia at the FDA. *Journal of the American Medical Association.* 1978;239(19):2004-11
http://dx.doi.org/10.1001/jama.1978.03280460072023


PS 7816  Landau RL. *What you should know about estrogens, or the perils of Pauline.* Rochester, NY: Center for the Study of Drug Development; Jun 1978


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://dx.doi.org/10.1046/j.1537-2995.1977.174772168


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1007/BF03284217

http://dx.doi.org/10.1056/NEJM197702032960505


http://dx.doi.org/10.1097/00012995-197608000-00001


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**